AstraZeneca PLC (BUE:AZN)
ARS 42025 -50 (-0.12%) Market Cap: 219.46 Tn Enterprise Value: 245.64 Tn PE Ratio: 33.69 PB Ratio: 5.51 GF Score: 64/100

AstraZeneca PLC Investor Science Conference Call: Farxiga's DAPA-HF trial at ESC Transcript

Sep 1, 2019 / 03:00 PM GMT


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AZN.L - AstraZeneca PLC
AstraZeneca PLC Investor Science Conference Call: Farxiga's DAPA-HF trial at ESC
Sep 01, 2019 / 03:00PM GMT

=====================
Conference Call Participants
=====================
* John McMurray;University of Glasgow
* Marco Metra;University of Brescia

=====================
Presentation
--------------------------------------------------------------------------------
John McMurray;University of Glasgow, [1]
--------------------------------------------------------------------------------
Thank you, Marco.

So I've got a whole lot of slides, but I'm actually not sure you want to see all of these slides. So my suggestion to you is that we maybe just try and put the trial into context unless somebody wants to see the mean results all over again. Does anybody want to see the mean results all over again? No? Okay.

So I'll tell you what, let's go to the end. So Marco showed a slide like this yesterday. I think this probably is the most important context slide. So just to read
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot